Our appreciation of the different molecular subtypes 1 and the complex genomic architecture of myeloma 2 has been recently enhanced by whole-exome and whole-genome DNA sequencing, indicating that myeloma cells typically harbor dozens of nonsynonymous mutations. 3, 4 Although myeloma is associated with recurrent mutations in a number of genes, including NRAS, KRAS, FAM46C, DIS3 and IRF4, 3 there is no evidence for hallmark 'unifying' mutations that have been found in other blood cancers, such as BRAF V600E in hairy cell leukemia 5 and MYD88 L265P in Waldenström macroglobulinemia. 6 The newly discovered myeloma alleles have raised the bar for preclinical mouse models of myeloma that can be used for interrogating pathways of tumor development and responses to new therapies. To rise to the challenge, more accurate, cost-effective and scalable models than what is currently available should be devised. In addition, next-generation mouse models of myeloma should be able to distinguish myeloma drivers from innocent bystander mutations, validate molecular targets for experimental myeloma interventions, elucidate mechanisms of acquired drug resistance and determine whether a myeloma gene operates in the tumor cells, the tumor microenvironment or both.
Encouraged by the push in the mouse cancer genetics community to supplement the time-consuming 'conventional' or 'germline' transgenic mouse models of cancer with more flexible and less expensive 'non-germline' models, 7 we have recently begun with the development of non-germline models for the in vivo validation of candidate myeloma genes. The cornerstone of the new method is adoptive B-cell transfer. Our first approach relied on Myc-transgenic cells. Although it provided proof-ofprinciple for the utility of adoptive B-cell transfer and showed that the tumor microenvironment is the critical source of interleukin (IL)-6 for neoplastic plasma cell (PC) development, 8 the requirement to prime the host mice with an intraperitoneal injection of pristane was a severe limitation. Treatment with pristane results in peritoneal plasmacytoma, an insufficient model for human myeloma. Here we demonstrate that this limitation can be overcome by employing a different type of B cell for the adoptive transfer: BCL2 + IL6
+ . This cell is prone to malignant transformation by virtue of classic oncogene collaboration; that is, a survivalenhancing BCL2 transgene 9 and a pro-inflammatory IL6 transgene.
10 BCL2 + IL6 + B cells can be readily isolated from secondary lymphoid tissues of double-transgenic mice (for example, spleen, mesenteric lymph node), genetically modified in vitro by viral gene transduction, and transferred to syngeneic BALB/c hosts primed with whole-body irradiation to facilitate the homeostatic expansion of the incoming B cells. The stable engraftment of these cells yields myeloma-like plasma cell neoplasms (PCNs) in immunocompetent hosts that have not been treated with intraperitoneal pristane (Figure 1a) .
To evaluate the potential of BCL2 + IL6 + B cells to give rise to myeloma-like tumors in genetically compatible hosts, B220 + CD45.2 + splenocytes were obtained from BCL2 + IL6 + mice and adoptively transferred, via retro-orbital IV injection, to CD45.1 + hosts pre-treated with a lethal dose of whole-body irradiation (Figure 1b, squares) . Tumor development was fully penetrant (100% tumor incidence) and tumor onset was short (61 days median, 50-80 days range) in all B-cell-reconstituted mice (n = 15). All tumors that arose from B cells that had been retrovirally transduced in vitro using a luciferase (Luc)-encoding cDNA gene exhibited strong reporter gene activity upon bioluminescence imaging in vivo (Figure 1c and Supplementary Figure 1) . Disappointingly, however, serum paraproteins were not detected (Supplementary Figure 2A) and the tumors were classified as diffuse large B-cell lymphoma (DLBCL) based on histopathologic criteria (Supplementary Figure 2B) .
To assess the possibility that the tumor pattern changes under conditions of less severe suppression of the host immune system, the tumor induction study was repeated using sub-lethally irradiated mice without bone marrow rescue (n = 12). Tumor onset was slowed (148 days median) and less predictable (64 days minimum, 353 days maximum) compared with lethally irradiated hosts, but tumor development was again complete (100% tumor incidence, Figure 1b Letters to the Editor dissemination pattern and extent of extra-medullary disease, 18 F-FDG-PET imaging was used. 11 Extra-medullary tumor load was modest ( Figure 1f ) relative to mice harboring IL-6/MYC-driven PCNs for which comparable PET data were available. 11 In keeping with the large M-spikes presented in Figure 1e , the PET results indicated that the malignant PCs exhibit a myeloma-like preponderance for hematopoietic bone marrow. To confirm that with an independent, quantitative method, we performed a flow-cytometric analysis of femural bone marrow samples, taking advantage of specific antibodies to CD45.2 and CD45.1, respectively, to unambiguously distinguish donor and host cells (Figure 1g, left) . In five of five cases that featured dense plasmacytic infiltrates in the femur, the tumors were donorderived, mature CD45.2 + CD138 + B220 − PCs (Figure 1g, center) . The low abundance of CD45. + tumors recapitulate the homing pattern of human myeloma.
To assess whether tumor manifestation in the bone marrow was accompanied by myeloma-like bone disease, we performed radiological and histochemical studies on the skeleton of PCNbearing mice. Quantitative bone analysis using Carestream planar radiography provided preliminary evidence for bone loss (not shown), but a more sensitive approach was desired. To that end, we employed high-resolution computed tomography (CT), which revealed skull and spine as apparent hotspots of bone disease.
The skull demonstrated separations and erosions of the coronal, sagittal and lambdoidal cranial sutures (Figure 2a) , reminiscent of changes seen in the Bcl-XL/iMyc model of myeloma. 12 CT imaging of the spine, using lumbar vertebrae L2-4 of tumor-bearing mice as indicator bones, demonstrated osteolytic perforations of the cortical bone (Figure 2b, left) . Agreeing with that, quantitative CT measurements of bone mass and secondary spongiosa showed a reduction in trabecular bone volume (Figure 2b , top right) and trabecular thickness (Figure 2b, center right) , and a concomitant increase in trabecular space and separation (Figure 2b , bottom right). These changes were confirmed in two-dimensional sections of L2-4, demonstrating discontinuities in the cortical ring (osteolytic lesions) and overall loss of cortical and trabecular bone (Figure 2c, left) . Additional evidence for the kind of highly active medullary disease that leads to generalized and focal osteopenia in patients with myeloma was provided by: BoneJ Thicknessgenerated graphical output data on trabecular bone mass ( Figure 2c, right) ; frequent detection of hindlimb paralysis in tumor-bearing mice (Figure 2d and Supplementary Movie) and striking increases in TRAP + (tartrate-resistant acid phosphatase) osteoclasts at the border of diseased bone and extensive sheets of malignant PCs (Figure 2e ) that completely effaced the normal hematopoietic elements of the marrow cavity.
Advantages of the new myeloma model described above include the possibility to (1) generate-de novo, and in a predictable, economic manner-'waves' of primary PCNs derived . Donor B cells were isolated with the assistance of the MACS B220 mouse B-cell kit from Miltenyi, were in some cases genetically modified in vitro by retroviral reporter gene (luciferase) transduction and were transferred to normal (not transgenic) CD45.1 + host mice that had been conditioned with whole-body irradiation a few hours before the cell transfer. Neoplasms arising in B-cell-reconstituted hosts were analyzed using a variety of immunological, imaging and histopathological methods, the results of which are presented in b to g of this figure and Figure 2 . Note that one donor mouse suffices to reconstitute 20-30 hosts, which mimic the clonal heterogeneity of human myeloma 4 by developing distinct tumors. See e for an example. Donor B cells at the time of harvest can be operationally defined as premalignant. However, their malignant potential is high, as all BCL2 + IL6 + mice spontaneously develop striking hypergammaglobulinemia by~3 months of age (Supplementary Figure 6) and PC tumors by~5 months of age (Supplementary Figure 7) . (b) Line graphs indicating tumor-free survival of B-cell reconstituted host mice pre-treated with either a sub-lethal dose (4.5 Gy, black circles) or lethal dose (11 Gy, black squares) of whole-body irradiation. The latter was administered as split dose (4.5 and 6.5 Gy, delivered 4 h apart) and required hematopoietic stem cell rescue using bone marrow transplantation (3 × 10 6 cells) for survival of mice. Median tumor-free survival of sub-lethally irradiated hosts (148 days; n = 12) was significantly longer than lethally irradiated hosts (61 days; n = 15) based on Mantel-Cox log-rank analysis (P o10 -3) , an age-matched normal C mouse used as control (image 4) and a PC tumor-bearing MYCIL6-transgenic mouse (image 5) that exhibited pronounced extraosseous disease in abdominal lymph nodes (red arrowhead pointing down) and spleen (red arrowhead pointing up). All images were normalized to the same maximal standard uptake value (SUV max ) to facilitate comparison of PET lesions. High FDG uptake and PET signal strength not associated with tumor burden is apparent in tissues with physiologically high levels of glucose utilization (for example, brain, heart) and in the FDG excretion pathway, particularly the urinary bladder. from the same donor B-cell pool, (2) employ in vivo imaging to evaluate myeloma bone disease (CT) and tumor development (bioluminescence imaging, PET) in live mice-in a reproducible, objective, sequential and, if desired, lesion-specific manner, (3) elucidate pleiotropic myeloma drivers, such as Bruton tyrosine kinase, 13 specifically in the 'seed' or 'soil' of myeloma-as recently demonstrated for IL-6 in plasmacytoma, 8 (4) study the mechanisms of and new treatments for myeloma bone disease and (5) tumor-bearing CD45.1 + mice that have achieved complete druginduced remissions, it may afford an extraordinary opportunity to shed light on long-standing, thorny questions in myeloma research; for example, the nature and anatomical location of stem cell-like myeloma cells, the biological underpinnings of minimal residual disease and the early events in tumor relapse. In sum, the findings reported here not only confirm two recent, insightful, independent studies on adoptive B-cell transfer mouse models of myeloma, 14, 15 they also provide a blueprint for the biological validation of candidate myeloma drivers as we go forward. + osteoclasts in PCN-bearing mice. TRAP (tartrate-resistant alkaline phoshatase) activity in osteoclasts (arrows) was detected using an acid phosphatase leukocyte kit from Sigma. Osteoclasts were enumerated in five high-power microscopy fields of each bone specimen. Five specimens per mouse were evaluated. Six tumor-bearing mice were compared with six normal controls. Mean values and s.e.m. of the two data sets were plotted.
